Core Viewpoint - The company aims to achieve revenue exceeding 15 billion yuan by 2030, with a focus on both existing and new product pipelines [1] Group 1: Revenue Goals - The company plans to generate approximately 9 billion yuan from existing pipeline sales and around 6 billion yuan from newly introduced pipeline sales, while also exploring potential license-out revenue [1] Group 2: Product Pipeline Focus - The company will concentrate on core areas such as nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology, aiming to develop a high-value product portfolio by 2030 [1] - The goal is to increase the number of commercialized products to over 20 by 2030 [1] Group 3: Strategic Approach - The company will adopt a dual approach of "BD collaboration + self-research" to drive growth, leveraging scientific insights and market understanding [1] - The company plans to introduce 3-5 mid-to-late stage blockbuster products annually through established BD capabilities and the Kangqiao ecosystem, aiming for peak sales within three years post-reimbursement for each product [1]
云顶新耀发布2030战略，聚焦肾科、自身免疫等核心方向